<DOC>
	<DOC>NCT01742585</DOC>
	<brief_summary>This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.</brief_summary>
	<brief_title>A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Chronic kidney disease patients (eGFR &lt; 60 mL/min/1.73 m2) Serum phosphorus measurement â‰§4.6 mg/dl, &lt;9.0 mg/dl Written informed consent Patients with gastrointestinal surgery or enterectomy Patients with severe cardiac diseases Patients with severe constipation or diarrhea Patients with a history or complication of malignant tumors Patients with uncontrolled hypertension Patients treated with parathyroid intervention within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Not on dialysis</keyword>
	<keyword>ASP1585</keyword>
	<keyword>Bixalomer</keyword>
</DOC>